Mature overall survival results of the INAVO120 trial were presented in a press conference for the American Society of ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Here is the complete list of stocks along with their key details that will remain in focus as they trade ex-dividend during ...

In its 28th year, the annual MPW list recognizes 100 women leading major global companies. This year, 21 listees are at the ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

The U.S. Food and Drug Administration has approved GSK plc (NYSE: GSK )’s asthma medication, Nucala, for expanded use in ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.